en · de · es · fr · pt
sr9009-notes.peptides6608.com › News › Sr9009 Background And Receptor Mechanism — 2026 Update

Sr9009 Background And Receptor Mechanism — 2026 Update

By Editorial Desk · published 2026-04-03 · last reviewed 2026-05-10 · News

This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-10. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

Background and Research Status

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Related pages on this site

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Notes from published material

In nuclear physics, beta decay (β-decay) is a type of radioactive decay in which an atomic nucleus emits a beta particle (fast energetic electron or positron), transforming into an isobar of that nuclide. For example, beta decay of a neutron transforms it into a proton by the emission of an electron accompanied by an antineutrino; or, conversely a proton is converted into a neutron by the emission of a positron with a neutrino in what is called positron emission. Neither the beta particle nor its associated (anti-)neutrino exist within the nucleus prior to beta decay, but are created in the decay process. By this process, unstable atoms obtain a more stable ratio of protons to neutrons. The probability of a nuclide decaying due to beta and other forms of decay is determined by its nuclear binding energy. The binding energies of all existing nuclides form what is called the nuclear band or valley of stability. For either electron or positron emission to be energetically possible, the energy release or Q value must be positive. Beta decay is a consequence of the weak force, which is characterized by relatively long decay times. Nucleons are composed of up quarks and down quarks, and the weak force allows a quark to change its flavour by means of a virtual W boson leading to creation of an electron/antineutrino or positron/neutrino pair. For example, a neutron, composed of two down quarks and an up quark, decays to a proton composed of a down quark and two up quarks.

Taco Bell opened its first Philippine branch in October 2004, at the Gateway Mall in Cubao, Quezon City. The Philippine franchisee is PPI Holdings, Inc. As of 2026, there are 12 outlets in the country, all in Metro Manila.

== Pharmacology == Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant nociceptin/orphanin-FQ peptide (NOP) receptors. It has a high degree of functional selectivity for the NOP receptor. Sunobinop is a low affinity antagonist at human mu and kappa opioid receptors, and is a low affinity weak partial agonist at human delta opioid receptors.

The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated

Sources: en.wikipedia.org

Background from the literature

In Indonesia the third-generation Familia was marketed by Indomobil Group twice, the first time as the 323 hatchback from 1977 to 1980, and the second time around as the low-cost alternative of the popular Toyota Kijang and fellow Indomobil Group product's Suzuki Carry Extra/Futura; low-price "Mazda MR90" (hatchback) between December 1990 to 1993, "Mazda Baby Boomers" (hatchback) between 1993 and 1995, and as the "Mazda Vantrend" (station wagon and special limited order as high roof van or pickup) between 1993 and 1997. The Vantrend and its derivatives were also marketed as the Mazda M1400. The name MR90 stands for "Mobil Rakyat 90" (people's car for the 1990s) as it was intended to become a national car project. This was scuppered by the appearance of the Timor 515 project. The MR90 and its successors did see limited exports to small markets such as Fiji and Sri Lanka. There was also a better equipped GLX version available. The Baby Boomers was a lightly facelifted variant with new bumpers and a rear spoiler, for a more sporty appearance overall. The 1990s versions built by Indomobil have modernized headlights (same as on the Mazda 626 (GC), while Vantrend adopted the pre-facelift North American market quad headlights version) and bumpers. These alterations mean that the overall length increased, up to 3,970 mm (156 in) for the MR90 hatchback. Only the 70 PS (51 kW) UC 1.4-litre engine was offered, in combination with a five-speed transmission.

Besides these methods, other techniques such as SELEX, PBM (protein binding microarrays), DNA microarray screens, DamID, FAIRE or more recently DAP-seq (DNA affinity purification sequencing) are used in the laboratory to investigate DNA-protein interaction in vivo and in vitro.

β-Carbolines and harmala alkaloids like harmine and harmaline contain DMT's close analogue NMT embedded in their structures. Triptans like sumatriptan, rizatriptan, eletriptan, almotriptan, frovatriptan, and zolmitriptan, which are antimigraine agents, all contain DMT in their structures. Similarly, the pertine antipsychotics including alpertine, milipertine, oxypertine, and solypertine are DMT derivatives. Bioisosteres of DMT in which the indole ring system has been replaced with a different ring system include isoDMT (an isoindole or isotryptamine), 2ZEDMA (an indolizine), and C-DMT (an indene), among others. The homologues of DMT in which the alkyl side chain has been shortened or lengthened by one carbon atom are gramine and dimethylhomotryptamine (DMHT), respectively. Further-extended homologues are also known. Deuterated isotopologues of DMT include deudimethyltryptamine (DMT-d10) or CYB004 (HLP004), SPL028 (D2-DMT; α,α-dideutero-DMT), and DMT-d4 (α,α,β,β-tetradeutero-DMT). Prodrugs of DMT such as 1-benzoyl-DMT and N-phosphonooxymethyl-DMT (N-POM-DMT) have also been described. Many of DMT's analogues and derivatives are serotonin receptor modulators and/or serotonergic psychedelics similarly to DMT itself.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network